Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07034690
PHASE4

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.

Official title: A Prospective, Type I Hybrid Effectiveness-implementation, Open Label, Randomized Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in at- Risk Adult Patients From Abu Dhabi, United Arab Emirates (UAE) With Dyslipidemia

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

326

Start Date

2025-11-26

Completion Date

2027-06-30

Last Updated

2026-01-30

Healthy Volunteers

No

Interventions

OTHER

Educational Material

Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)

OTHER

Standard of care

Standard of care

Locations (1)

Novartis Investigative Site

Abu Dhabi, United Arab Emirates